Influence of the introduction of an electronic diabetes management system in patients with type 2 diabetes mellitus on a medical ward.

Influence of the introduction of an electronic diabetes management system in patients with type 2 diabetes mellitus on a medical ward. - Dokumentation_GlucoTab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016983

Enrollment

400

Registered

2019-12-12

Start date

2017-03-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11

Interventions

Group 1: In this retrospective data analysis data were compared 6 months before and 6 months after the introduction of the electronic diabetes management system (GlucoTab) on a medical ward.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: •Type 2 diabetes mellitus or recent / diagnosed hyperglycaemia • Age> 18 years • treatment with "free therapy"

Exclusion criteria

Exclusion criteria: •Type 1 diabetes mellitus, pancreoprive diabetes, gestational diabetes • Pregnancy • Continuous parenteral nutrition • IV insulin therapy • Treatment with the decision support component of GlucoTab®

Design outcomes

Primary

Measure	Time frame
Mean daily blood glucose level	—

Secondary

Measure	Time frame
• Number of daily blood glucose measurements • Oral antidiabetics • Insulin doses (basal insulin, bolus insulin, mixed insulin, daily insulin, and correction insulin dose) • Midprandial (morning, noon, evening) and bedtime blood glucose • hypoglycaemia ( 180mg / dl,> 200mg / dl,> 300mg / dl) • concomitant medication that influences the glucose metabolism (eg cortisone) • Number of patients receiving free therapy (paper-based or GlucoTab®-based) vs. Decision Support Therapy according to GucoTab® • Blood glucose control comparison with GlucoTab® decision support vs. free therapy	—

Measure

Time frame

• Number of daily blood glucose measurements • Oral antidiabetics • Insulin doses (basal insulin, bolus insulin, mixed insulin, daily insulin, and correction insulin dose) • Midprandial (morning, noon, evening) and bedtime blood glucose • hypoglycaemia ( 180mg / dl,> 200mg / dl,> 300mg / dl) • concomitant medication that influences the glucose metabolism (eg cortisone) • Number of patients receiving free therapy (paper-based or GlucoTab®-based) vs. Decision Support Therapy according to GucoTab® • Blood glucose control comparison with GlucoTab® decision support vs. free therapy

—

Countries

Austria

Contacts

Public ContactJulia Mader

LKH Universitätsklinikum Graz Abteilung für Endokrinologie & Diabetologie

julia.mader@medunigraz.at+43 316 385 80254

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026